EUCTR2021-000037-14-NL进行中（未招募）1 期
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Aged =18 years and legal age of consent according to local regulations
- •2.Newly diagnosed and AL amyloidosis treatment naive with cardiac involvement
- •3.Confirmed diagnosis of AL amyloidosis
- •4.Confirmed Mayo Stage IV AL Amyloidosis as defined by NT-proBNP =1800 pg/mL and Troponin-T =0.025 ng/mL (mcg/L) or high sensitivity
- •cardiac troponin T =40 ng/L and dFLC =18 mg/dL
- •5.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly
- •A comprehensive list of inclusion criteria can be found in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •1.Non-AL amyloidosis
- •2.NT-proBNP >8500 pg/mL
- •3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma, except for malignancy biomarker of involved/and uninvolved serum free light chain ratio =100
- •4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study
- •5.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
- •6.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease
- •7.ECG evidence of acute ischemia or active conduction system abnormalities
- •8.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1
- •9.Prior radiotherapy within 4 weeks of Month 1-Day 1
- •10.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11-1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid
- •11.Waldenström's macroglobulinemia and/or immunoglobulin M monoclonal gammopathy
- •A comprehensive list of exclusion criteria can be found in the protocol.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza.MedDRA version: 14.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2009-012367-34-BGBioCryst Pharmaceuticals, Inc.600
招募中
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-NOCelgene International II Sàrl485
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's DiseaseEUCTR2018-004614-18-HUEli Lilly and Company1,150
进行中（未招募）
1 期
The study of an investigational drug, Cenicriviroc, for the treatment of liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH).iver fibrosis in Subjects with Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-004566-26-BETobira Therapeutics Inc., a subsidiary of Allergan plc2,000
进行中（未招募）
1 期
A Phase 3 Study in Moderate to Severe Chronic Psoriasis PatientsMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858Plaque PsoriasisEUCTR2014-003492-36-BGCB Biopharma, SPR561